logo
Trump's FDA pick made his name by bashing the medical establishment. Soon he may be leading it

Trump's FDA pick made his name by bashing the medical establishment. Soon he may be leading it

WASHINGTON — Dr. Marty Makary rose to national attention by skewering the medical establishment in books and papers and bashing the federal response to COVID-19 on TV.
Now the Johns Hopkins University surgeon and researcher has been nominated to lead the Food and Drug Administration. The agency — responsible for regulating products ranging from toothpaste to vaccines — is famously understated, issuing carefully worded statements devoid of opinion or scientific speculation.
That's the opposite approach of Makary, whose sweeping rhetoric and biting criticism often veer into hyperbole, according to a review of recent speeches, interviews and podcast appearances by the Associated Press.
Makary has called the U.S. food supply 'poison,' says the federal government is the 'greatest perpetrator of misinformation' about COVID-19 and regularly suggests that pesticides, fluoride and overuse of antibiotics may be to blame for rising rates of infertility, attention deficit disorder and other health conditions. He'll appear Thursday before a Senate panel considering his nomination.
Makary's views align with those of the man who would be his boss: Robert F. Kennedy Jr., the U.S. Health secretary who built a following by sowing doubts about vaccines, ultraprocessed foods and fluoride. Notably, Makary has never embraced Kennedy's discredited idea that vaccines might cause autism.
Experts who have worked with Makary say his contrarian approach could be useful at the FDA — but only if he's able to resist political pressure from Kennedy and others on hot-button issues like vaccines.
'He has this reputation of being someone who cares about evidence and transparency,' said Dr. Reshma Ramachandran of Yale University, who was part of an informal research group with Makary. 'The question is whether he's going to preserve and defend the integrity of the agency or is he going to fall in line with the administration.'
Makary did not respond to an AP interview request.
Trained as a pancreatic surgeon, Makary focused his initial work on uncontroversial topics like hospital costs and surgical checklists.
In 2016, he made headlines with a paper stating that medical errors were 'the third leading cause of death in the U.S.' That conclusion was quickly disputed by other experts, who said the paper's death estimate was 10 times higher than more rigorous reviews.
During the COVID-19 pandemic, Makary reached a much broader audience as a regular on Fox News, where he opposed vaccine mandates and called the FDA 'broken' and 'mired in politics and red tape.'
Makary often directs his harshest criticism toward the 'medical hubris' of fellow doctors, as in his latest book 'Blind Spots,' which catalogues a number of cases where experts 'got the science perfectly backwards.'
For example, he examines early recommendations that parents delay giving babies peanut-based foods due to allergy risks. Today, pediatricians generally recommend earlier introduction to prevent food allergies.
Many researchers view such examples differently.
'These are cases of people doing the best they can with evolving information and needing to make decisions along the way,' said Dr. Aaron Kesselheim of Harvard Medical School. 'As commissioner, he's going to have to be OK with making decisions based on evolving evidence — and some of those decisions might be wrong.'
Like others in Kennedy's 'Make America Healthy Again' movement, Makary says many of the chronic health problems afflicting Americans may be related to food additives, pesticides and other chemicals.
'How about research on the pesticides that have hormone effects in children that may explain the declining fertility and lowering age of puberty?' Makary asked, in a September podcast with Dr. Drew Pinsky.
New York University food researcher Marion Nestle says Makary's questions 'are extremely difficult to settle,' because there's no way to ethically do the type of research needed to reach a firm conclusion: give one group of children food with pesticides and compare them with a control group getting food not grown with pesticides.
'I sympathize with his frustration and think we would be much better off with a lot fewer pesticides in our food supply, but I tend to view these issues more cautiously,' Nestle said.
Nutrition experts also say it's overly simplistic to declare all ultraprocessed foods harmful, since the category includes an estimated 60% of U.S. foods, including granola, peanut butter and ice cream.
'They are not all created equal,' said Gabby Headrick of George Washington University. 'It is much more complicated than just pointing the finger at ultraprocessed foods as the driver of chronic disease in the United States.'
'The greatest perpetrator of misinformation during the pandemic has been the United States government,' Makary told House lawmakers during a 2023 roundtable hosted by Republicans.
Among the many COVID-19 policies Makary attacked was the recommendation for booster shots in teens and young adults, particularly boys and young men. That group received particular attention because early vaccinations showed a higher rate of myocarditis, a rare form of heart inflammation that is usually mild. Complicating the issue was the fact that COVID-19 itself also caused cases of myocarditis that were usually more severe.
A 2022 paper co-authored by Makary concluded that requiring booster shots in young people would cause more injury than benefit. None of the authors specialized in studying infectious diseases or vaccine reactions.
'They made mistake after mistake and every time it either minimized the vaccine's benefits or exaggerated the risks,' said Dr. Robert Morris of the University of Washington, who published a critique of the work. 'This paper really fed the whole notion that the vaccine is worse than the disease.'
Makary's conclusion contradicted that of U.K. experts and the Centers for Disease Control and Prevention, which estimated the booster prevented 114 hospitalizations for every seven it caused in young people.
Despite such pushback, Makary told Congress that CDC and FDA 'lied to the American people' about the need for boosters and other COVID measures.
Dr. Paul Offit, an FDA vaccine advisor, says the Biden administration made missteps in rolling out boosters, including announcing plans to make them available for all age groups before outside experts had weighed in. But, Offit said, Makary's language has damaged public trust in health institutions, including the one he's been picked to lead.
'It's rhetoric that's purposefully inflammatory to win over a certain crowd, which is part of today's zeitgeist of disdaining public health agencies,' Offit said. 'So he's offered the position at FDA because he has disdain for the agency.'
Perrone writes for the Associated Press. AP writer Lauran Neergaard contributed to this story.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mike Johnson Offers Bizarre Justification For ICE Masks. Backlash Follows.
Mike Johnson Offers Bizarre Justification For ICE Masks. Backlash Follows.

Yahoo

time31 minutes ago

  • Yahoo

Mike Johnson Offers Bizarre Justification For ICE Masks. Backlash Follows.

House Speaker Mike Johnson (R-La.) faced criticism after he defended the wearing of masks by Immigration and Customs Enforcement (ICE) agents during immigration raids. Johnson was asked by Fox News to respond to concerns from Democrats who say ICE agents shouldn't conceal their identities while conducting arrests as part of the Trump administration's immigration crackdown. 'From the people who mandated mask-wearing for years in America, it's absurd,' Johnson fired back, referencing the face-covering measures that Democrats implemented during the coronavirus pandemic in a bid to stop the spread of COVID-19. 'They need to back off of ICE and respect our agents and stop protesting against them,' he added, arguing that agents would be doxed if they were able to be identified. Critics pointed out the irony of Johnson's acceptance of agents wearing masks, given his history of opposing mask mandates for medical reasons, and suggested he had conjured up an extreme example of false equivalence. Agents should be able to be held accountable, they argued. Johnson was also criticized over the weekend for dismissing concerns about Defense Secretary Pete Hegseth's talk of active-duty Marines tackling protests against immigration enforcement in Los Angeles. 'I don't think that's heavy-handed,' Johnson said. Karoline Leavitt Squirms Over Maria Bartiromo's Blunt Question About Elon Musk Trump Accused Of Inciting Violence With Chilling New Rhyme German Leader Politely Shuts Down Trump's Hot Take On D-Day

Why has there been a global surge of new Covid variant NB.1.8.1?
Why has there been a global surge of new Covid variant NB.1.8.1?

Yahoo

time40 minutes ago

  • Yahoo

Why has there been a global surge of new Covid variant NB.1.8.1?

India is the latest country to report a surge in new Covid cases, as the latest variant NB.1.8.1 spreads across the globe. Cases have now been reported in Asian countries such as Thailand, Indonesia and China, while the UKHSA recorded the first 13 cases in England last week. However, the true numbers are unlikely to be known, given the significant decrease in the number of people testing compared to the figures seen during the global pandemic five years ago. NB.1.8.1 stemmed from the Omicron variant and was first detected in January this year. It has quickly spread across China and Hong Kong, and has now been recorded in several states across the United States and Australia. By late April, NB.1.8.1 comprised about 10.7 per cent of submitted sequences globally, according to the World Health Organization (WHO). This rose from just 2.5 per cent one month before. The WHO declared the NB.1.8.1 strain a 'variant under monitoring' on 23 May, which means scientists believe it could potentially affect the behaviour of the virus. Lara Herrero, a virologist from Griffith University in Australia, suspects that NB.1.8.1 spreads more easily than other variants. 'Using lab-based models, researchers found NB.1.8.1 had the strongest binding affinity to the human ACE2 receptor of several variants tested, suggesting it may infect cells more efficiently than earlier strains,' Dr Herrero wrote last month in The Conversation. Dr Chun Tang, GP at Pall Mall Medical, added: 'NB.1.8.1 isn't too different from the Omicron variant, but it does have some tweaks to its spike protein, which might make it spread a bit more easily or slip past some of our existing immunity. 'That said, early signs suggest it doesn't seem to cause more serious illness, but of course, we're still learning more about it.' 'Its spread has been identified in around 22 countries,' said Dr Naveed Asif, GP at The London General Practice. 'The WHO assesses the additional risk to the global public as currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease.' However, Nimbus does appear to be more transmissible than previous variants, with notable increases reported in India, Hong Kong, Singapore, and Thailand, notes Dr Asif. Common symptoms of the NB.1.8.1 variant include a severe sore throat. fatigue, mild cough, fever, muscle aches and congestion. It has also been reported that some patients have experienced gastrointestinal symptoms such as nausea and diarrhoea. Healthcare experts have stressed, however, that there is no evidence that the new strain is more deadly or serious than previous variants, and that current Covid vaccines are expected to remain effective and protect anyone infected from severe illness.

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Miami Herald

time41 minutes ago

  • Miami Herald

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).9.1 point average rVCSS improvement among the responder cohort.A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store